Patents by Inventor Sher Bahadur Karki

Sher Bahadur Karki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fc variants with altered binding to FcRn
    Patent number: 11932685
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: March 19, 2024
    Assignee: XENCOR, INC.
    Inventors: Aaron Keith Chamberlain, Bassil Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • OPTIMIZED ANTIBODIES THAT TARGET CD19
    Publication number: 20230340144
    Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.
    Type: Application
    Filed: February 21, 2023
    Publication date: October 26, 2023
    Inventors: Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik Weiking Pong, John O. Richards, Eugene Alexander Zhukovsky
  • METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS IN IGG4-RELATED DISEASES
    Publication number: 20230227560
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: August 11, 2022
    Publication date: July 20, 2023
    Applicant: Xencor, Inc.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • Optimized antibodies that target CD19
    Patent number: 11618788
    Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: April 4, 2023
    Assignee: XENCOR, INC.
    Inventors: Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik Weiking Pong, John O. Richards, Eugene Alexander Zhukovsky
  • Methods and compositions for inhibiting CD32B expressing cells
    Patent number: 11447552
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: September 20, 2022
    Assignee: XENCOR, INC.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • Fc VARIANTS WITH ALTERED BINDING TO FcRn
    Publication number: 20220281964
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Application
    Filed: May 17, 2022
    Publication date: September 8, 2022
    Inventors: Aaron Keith Chamberlain, Bassil Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Methods and compositions for inhibiting CD32B expressing cells
    Patent number: 11434295
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: September 6, 2022
    Assignee: XENCOR, INC.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • Fc VARIANTS WITH ALTERED BINDING TO FcRn
    Publication number: 20220112307
    Abstract: The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.
    Type: Application
    Filed: December 13, 2021
    Publication date: April 14, 2022
    Inventors: Aaron Keith Chamberlain, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Jost Vielmetter, Sean C. Yoder
  • METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
    Publication number: 20210395363
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: August 30, 2021
    Publication date: December 23, 2021
    Applicant: XENCOR, INC.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • Fc variants with altered binding to FcRn
    Patent number: 11198739
    Abstract: The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: December 14, 2021
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Jost Vielmetter, Sean C. Yoder
  • Fc VARIANTS WITH ALTERED BINDING TO FcRn
    Publication number: 20210277095
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Application
    Filed: October 23, 2020
    Publication date: September 9, 2021
    Inventors: Aaron Keith Chamberlain, Bassil Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Fc VARIANTS WITH ALTERED BINDING TO FcRn
    Publication number: 20210115118
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Application
    Filed: March 25, 2020
    Publication date: April 22, 2021
    Inventors: Aaron Keith Chamberlain, Bassil Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Fc VARIANTS WITH ALTERED BINDING TO FcRn
    Publication number: 20210115147
    Abstract: The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.
    Type: Application
    Filed: August 4, 2020
    Publication date: April 22, 2021
    Inventors: Aaron Keith Chamberlain, Bassil Dahiyat, John Desjarlais, Sher Bahadur Karki, Gregory Lazar
  • METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
    Publication number: 20210009690
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: September 24, 2020
    Publication date: January 14, 2021
    Applicant: XENCOR, INC.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
    Publication number: 20210009689
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: September 23, 2020
    Publication date: January 14, 2021
    Applicant: XENCOR, INC.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • OPTIMIZED ANTIBODIES THAT TARGET CD19
    Publication number: 20200317804
    Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.
    Type: Application
    Filed: April 1, 2020
    Publication date: October 8, 2020
    Applicant: XENCOR, INC.
    Inventors: Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik Weiking Pong, John O. Richards, Eugene Alexander Zhukovsky
  • Fc VARIANTS WITH ALTERED BINDING TO FcRn
    Publication number: 20200262899
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Application
    Filed: February 27, 2020
    Publication date: August 20, 2020
    Inventors: Aaron Keith Chamberlain, Bassil Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Fc VARIANTS WITH ALTERED BINDING TO FcRn
    Publication number: 20200255502
    Abstract: The present application relates toa variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Application
    Filed: June 12, 2019
    Publication date: August 13, 2020
    Inventors: Aaron Keith Chamberlain, Bassil Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Optimized antibodies that target CD19
    Patent number: 10626182
    Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: April 21, 2020
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik Weiking Pong, John O. Richards, Eugene Alexander Zhukovsky
  • Fc variants with increased affinity for Fc?RIIc
    Patent number: 10584176
    Abstract: The present invention relates to Fc variants having increased affinity for Fc?RIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: March 10, 2020
    Assignee: Xencor, Inc.
    Inventors: Gregory Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes